Decreased survival and increased recurrence in Merkel cell carcinoma significantly linked with immunosuppression. Issue 4 (20th June 2020)

• Record Type: Journal Article
• Authors: Bryant, Mary K.; Ward, Christine; Gaber, Charles E.; Strassle, Paula D.; Ollila, David W.; Laks, Shachar
• Is Part Of: Journal of surgical oncology. Volume 122:Issue 4(2020)
• Page Start: 653
• Page End: 659
• Publication Date: 2020-06-20
• Subjects: immunosuppression -- Merkel cell carcinoma -- prognosis; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26048
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background: Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer. It is an immunogenic tumor as evident by its association with Polyomavirus, immunotherapy response, and increased prevalence in the immunosuppressed population. Objective: We sought to evaluate the impact of known clinicopathological determinants and immunosuppression on the risk of recurrence and mortality of MCC patients. Methods: A retrospective, observational cohort study of patients diagnosed and/or treated with MCC at two tertiary academic institutions. We compared clinicopathological determinants, treatment modalities, and immunosuppression status on clinical outcomes of recurrence, disease‐specific survival, and overall survival. Results: We evaluated 90 patients within our study and 34% had a cancer recurrence during follow‐up. Patients with recurrence were significantly more likely to be immunosuppressed (32% vs 5%; P = .001). Estimated 5‐year recurrence was 43%, and immunosuppressed patients were significantly more likely to recur (Hazard ratio [HR] 3.67 [1.80‐7.51]; P < .0001). Immunosuppressed patients had significantly elevated cancer‐specific mortality (HR 6.11[1.61‐23.26]; P = .008). Limitations: Retrospective review with a prolonged observation period and changing treatment modalities. Conclusion: Immunocompromised patients had a threefold increased incidence of 5‐year mortality and over twofold increased incidence of any recurrence as non–immunocompromised patients. Patients' immunosuppressive status should be considered when making decisions regarding treatment, surveillance, and prognostication.